Abstract

In this study, we investigated the capability of polygenic risk scores to stratify a cohort of young individuals into risk deciles based on 10 different cardiovascular traits and circulating biomarkers. We first conducted large-scale genome-wide association studies using data on adults (mean age 56.5 years) enrolled in the UK Biobank study (n=393 193 to n=461 460). Traits and biomarkers analyzed were body mass index, systolic blood pressure, diastolic blood pressure, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, apolipoprotein B, apolipoprotein A-I, C-reactive protein and vitamin D. Findings were then leveraged to build whole genome polygenic risk scores in participants from the Avon Longitudinal Study of Parents and Children (mean age, 9.9 years) which were used to stratify this cohort into deciles in turn and analyzed against their respective traits. For each of the 10 different traits assessed, we found strong evidence of an incremental trend across deciles (all P<0.0001). Large differences were identified when comparing top and bottom deciles; for example, using the apolipoprotein B polygenic risk scores there was a mean difference of 13.2 mg/dL for this established risk factor of coronary heart disease in later life. Although the use of polygenic prediction in a clinical setting may currently be premature, our findings suggest they are becoming increasingly powerful as a means of predicting complex trait variation at an early stage in the lifecourse.

Highlights

  • In this study, we investigated the capability of polygenic risk scores to stratify a cohort of young individuals into risk deciles based on 10 different cardiovascular traits and circulating biomarkers

  • CONCLUSIONS: the use of polygenic prediction in a clinical setting may currently be premature, our findings suggest they are becoming increasingly powerful as a means of predicting complex trait variation at an early stage in the lifecourse

  • Polygenic risk scores (PRS) involve the aggregation of genetic variants scattered throughout the human genome to index an individual’s genetic risk of disease.[1]. Their use in applied research has become increasingly popular in recent years, their diagnostic capabilities in clinical settings remains a contentious point of discussion.[2]

Read more

Summary

Methods

We first conducted large-scale genome-wide association studies using data on adults (mean age 56.5 years) enrolled in the UK Biobank study (n=393 193 to n=461 460). Traits and biomarkers analyzed were body mass index, systolic blood pressure, diastolic blood pressure, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol triglycerides, apolipoprotein B, apolipoprotein A-I, C-reactive protein, and vitamin D. We conducted 10 GWAS in the UKB study on the following traits; body mass index (field No 21001), systolic blood pressure (field No 4080), diastolic blood pressure (field No 4079), HDL-C (high-density lipoprotein cholesterol; field No 30760), LDL-C (low-density lipoprotein cholesterol; field No 30780), triglycerides (field No 30870), apolipoprotein B (field No 30640), apolipoprotein A-I (field No 30630), C-reactive protein (field No 30710), and vitamin D (field No 30890; Table S1).

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call